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Abstract  
 
Context. At present there is no widely used systematic, evidence-based holistic approach to 
assessment of patients’ supportive and palliative care needs.   
 
Objectives. To determine whether the use of a holistic needs assessment questionnaire, 
SPARC, will lead to improved health care outcomes for patients referred to a palliative care 
service. 
 
Methods. Open pragmatic randomised controlled trial. 182 patients referred to the palliative 
care service were randomised to receive SPARC at baseline (n=87) or after a period of two 
weeks (waiting list control n=95). Primary outcome measure: Difference in score between 
MYCAW patient-nominated concern 1 on the patient self-scoring visual analogue scale at 
baseline and the two-week follow up. Secondary: difference in scores in the MYCAW, EQ-
5D, and PEI scores at weeks 2, 4 and 6.  
 
Results. There was a significant association between change in MYCAW score and whether 
the patients were in the intervention or control group (χ
2
trend = 5.51; df = 1; p = 0.019). A 
higher proportion of patients in the control group had an improvement in MYCAW score 
from baseline to Week 2: Control: 34/70 (48.6%) vs. Intervention: 19/66 (28.8%). There were 
no significant differences (no detectable effect) between the control and intervention groups 
in the scores for EQ5D and PEI at 2, 4, or 6 weeks follow up.   
 
Conclusion. This trial result identifies a potential negative effect of SPARC in specialist 
palliative care services, raising questions that standardised holistic needs assessment 
questionnaires may be counter-productive if not integrated with a clinical assessment that 
informs the care plan.  
 
Key Words: Palliative care, holistic needs assessment questionnaire, SPARC, MYCAW, 
EQ5D. 
Running Title: Palliative Care Holistic Needs Assessment RCT. 
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Introduction  
 
The Sheffield Profile for Assessment and Referral for Care (SPARC) (Appendix 1) is a 
multidimensional holistic needs assessment questionnaire, designed to identify patients who 
may benefit from additional supportive or palliative care, regardless of diagnosis or stage of 
disease. SPARC is intended for use by primary care, hospital teams or other services to 
improve patient management, either by current professional carers or by referral to a 
specialist team. The patient-rated (self-complete) 45-item questionnaire reflects nine 
dimensions of need and as such represents a comprehensive early needs assessment or 
holistic questionnaire.
1
 It is capable of being completed by patients unassisted, or, for those 
prevented by disability from reading or writing responses, with the help of their informal or 
professional carers.
2
. Despite rigorous psychometric development, preliminary field-testing, 
and validation
1,2,3,4,5,6
, the clinical utility of SPARC has yet to be established, either as an aid 
to specialist clinical assessment or as a screening tool.
 7
  
 
There is evidence to suggest that patients with cancer and non-malignant chronic progressive 
illnesses can experience distressing symptoms and concerns, which may remain 
unrecognised.
7,8,9,10
 Previous research has highlighted that distressing symptoms and concerns 
can be managed, provided they are identified in a timely manner and systems are in place for 
a prompt referral to specialist teams.
11,12,13,14,15,16
 The timely identification of needs and 
prompt referral to specialist teams could reduce the burden of suffering and lead to earlier 
discharge. Similarly, earlier detection of these problems in out-patients or the community 
might prevent unnecessary admissions. These potential health gains might accrue for a 
relatively small investment.
7
 However, at present there is no widely used systematic, 
evidence-based holistic approach to assessing patients for supportive and palliative care 
needs. There is a lack of studies on the clinical utility of tools.
1,7
 
 
We conducted a pilot pragmatic, randomised, controlled trial to determine whether the use of 
SPARC leads to improved health care outcomes (health-related quality of life and self-
identified concerns) for patients referred to a palliative care service, to guide the development 
of a definitive multicentre study. This study represents a development of SPARC for use as 
an early holistic needs assessment questionnaire within a specialist service. This study does 
not test the utility of SPARC as a screening questionnaire for specialist palliative care. 
Palliative care interventions are complex, and in light of this, the SPARC study was 
developed, piloted, evaluated, reported and implemented in accordance with the Medical 
Research Council framework for developing and evaluating complex interventions (new 
guidance).
17,18,19 
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Methods 
The trial is reported in accordance with the CONSORT 2010 statement.
20
 
  
Trial design and recruitment  
This open, randomised, controlled trial employed a waiting-list control design.
21
 All patients 
referred to the supportive and palliative care service that met the study inclusion criteria were 
invited to take part in the study. Invitations to participate were sent by post (outpatients and 
those in the community), or given face to face (inpatients and day care patients). Patients who 
consented to taking part in the study were randomised to receive the SPARC questionnaire at 
baseline (Intervention group) or after a two-week period (Control group).  
 
Participants  
Inclusion criteria  
1. Any diagnosis (cancer and non-cancer). 
2. Any referral to the palliative care service in any care setting. 
3. Patients 18 years old or above. 
4. Patients able to give informed consent. 
 
Exclusion criteria  
1.  Patients incapable of giving informed consent.  
2.  Patients incapable of completing SPARC even with the help of a relative or 
informal carer. 
3.  Patients under 18 years old. 
 
Stratification  
Baseline quality of life may confound response to an intervention by reversion to the mean, 
so patients were stratified for baseline EQ-5D thermometer score. Thus, patients completing 
the consent form were also asked to complete the EQ-5D thermometer (score) before 
randomisation. Based on previous work
22,23
, the research team set the EQ-5D thermometer 
score at 40. Patients scoring 40 or above at baseline were placed in the median and above 
(MA) group, and those scoring less than 40 were placed in the below median (BM) group. 
 
 
Sheffield palliative care service context and settings  
Patients were recruited from the whole range of settings (in-patients, outpatients, day care 
and from the community) which included the two hospitals within the city, a palliative care 
unit, a hospice and from the community via a team of community specialist nurses. Over 
2000 patients a year are referred to these services, including those with long-term conditions 
and cancer survivors as well as those needing end of life care.  
 
Intervention (SPARC) 
Those patients who consented were randomised to receive the SPARC questionnaire (Table 
1: follow up procedure) at baseline (intervention group), or after a two-week waiting list 
period (control group). All patients received on-going care as usual. A completed paper copy 
of SPARC was sent to the health care professional (HCP) caring for the patient to prompt 
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action on needs identified by SPARC. The SPARC questionnaire data was also kept in the 
patients’ notes and a copy was kept on the electronic clinical record. Follow-up study 
questionnaires were administered either face to face or by post. The 2-week point was 
selected as the crucial follow-up measure following baseline in order to minimize attrition.  
 
Outcome measures 
Study participants were required to complete three validated brief self-complete research 
outcome measures namely; the MYCAW (Measure Yourself Concerns and Wellbeing); the 
EQ-5D (measure of health-related quality of life) and PEI (The Patient Enablement 
Instrument) at baseline, week 2, week 4 and week 6 respectively (Appendix 2). The rationale 
for the choice of outcome measures is presented in Table 2.
24-30
 
 
Primary outcome:  
• The change in MYCAW score between the first MYCAW patient nominated concern 
at baseline and the two-week follow up. This is the nominated first concern.   
 
Secondary outcomes: 
• The change in scores in the EQ-5D at the two time points. 
• Changes in the enablement scores (PEI) at the two time points. 
• Comparisons of MYCAW patient nominated concerns, EQ-5D, and the PEI at 
baseline between patient groups. 
• The pattern of actions taken and referrals made as a result administering the SPARC 
screening tool were examined by analysis of the clinical record (to be reported 
elsewhere).  
 
Randomisation 
A set of sequentially-numbered, opaque, sealed, A4 envelopes containing all study 
documents were set up for each care setting (henceforth called the study pack). The 
randomisation process was undertaken by a member of the study team (MW), who then 
identified which study packs were for the intervention arm and which were for the control 
arm of the study. A copy of the SPARC questionnaire (Appendix 1) was added to the study 
packs for the intervention arm and 182 patients were randomised with computer generated 
random numbers in pre-paid sealed envelopes to receive SPARC at baseline (n=87) or after a 
period of two weeks (waiting list control n=95).  
 
Recruitment 
For inpatients, and day-care patients, a health care professional informed the patient about the 
study and asked whether they were willing to participate in the study. Contact details of 
patients who indicated that they were willing to participate were then passed to a member of 
the study team. Community patients and outpatients were sent study packs via medical 
secretaries (the list of patients was first agreed with the health care professional with 
responsibility for the care of these patients). Upon receiving consent, the researcher (NA), 
who was blinded to the study collected the next sequentially-numbered, opaque, sealed 
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envelope and hand-delivered it to inpatients, or sent it via post to community patients and 
outpatients.  
 
Statistical methods and analysis 
Primary end-point analysis 
The primary outcome measure was the difference in score between the patient nominated 
concern (MYCAW, concern 1) on the patient self-scoring visual analogue scale at baseline 
and the two-week follow up. Assuming the changes in the score (baseline to week 2)  would 
be normally distributed, it was planned to carry out a t-test to test the null hypothesis that the 
difference between the intervention and control groups in the mean score on the first 
symptom nominated on the scale at baseline and two weeks is 0. However, because the data 
were not normally distributed, the Mann Whitney test was used to test for difference in the 
two groups in the rankings of the Week 2, 4, and 6 scores and the rankings of the change in 
scores from Baseline to Weeks 2, 4 and 6.  
 
Statistical power 
To detect a medium-sized difference between two independent sample means at alpha = 0.05, 
beta = 0.80 required a minimum of 64 individuals in each group with scores at baseline and 
two weeks.
31
 Therefore, a total of 128 patients would have to be recruited.  
 
The power of the study was based on the RCT with the group of patients from whom it would 
be possible to obtain follow up data. Differences between the control and intervention groups 
were tested using t-tests to compare the mean scores at Weeks 2, 4, 6, and the mean change in 
scores from Baseline to Week 2, 4 and 6.  
 
Secondary and exploratory analysis  
Statistical analysis of the comparisons between patient groups for the secondary outcomes 
involved both descriptive analyses and statistical tests.  A qualitative content analysis
32, 33
 of 
the nominated first concern and the nominated second concern was undertaken at baseline. 
The concerns named in MYCAW were analysed qualitatively using a summative content 
analysis approach. Stated concerns were examined for keywords and themes, with the context 
taken into account for the final interpretation. Analysis of the data from patient semi-
structured interviews, health care professional interviews
34
, case note reviews and from the 
supplementary question about patients’ experience of completing SPARC will be presented 
elsewhere (process evaluation).   
 
Results 
Recruitment and attrition rates  
A total of 850 patients were invited to take part in the study, of which 225 consented to take 
part (225/850=26.5% response rate), 182 patients completed baseline questionnaires, 152 
completed the 2 week questionnaires, 126 completed the 4 week questionnaires, and 120 
completed the 6 week questionnaires. The critical point in the analysis was the 2 week point, 
the point at which patients in Group A (intervention arm) had already received the SPARC 
intervention, and patients in Group B (control arm) had not yet received the SPARC 
intervention. Seven patients did not complete the trial, citing questionnaire completion and 
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taking part in the trial too burdensome as reasons for not continuing to take part. Two patients 
expressed concern around issues of data collection, and had anticipated more face-to-face 
contact visits as opposed to receiving postal questionnaires. At the end of the trial (eight 
weeks after completion of baseline questionnaires), 23 patients had died, and 159 patients 
were alive. There was no significant difference in the number of deaths between the 
intervention and control groups. In Group A (Intervention), nine people (10.3%) died within 
the 8-week study period and in Group B (Control), fourteen people (14.7%) died within the 
8-week study period. A summary of the recruitment is presented in Figure 1. ∀
∀
Participants and settings 
Baseline data ∀
Of the 182 study participants, 84 were male (46.2%) and 98 were female (53.8%). The mean 
age of the participants on trial registration was 64.47 years (median = 66.00 years; SD = 
12.57; minimum age = 27 years; maximum age = 90 years). There were 87 (47.8%) 
participants in the intervention arm (Group A), and 95 (52.2%) participants in the control arm 
(Group B) of the study; there was no significant difference in the partnership status of 
patients in Groups A vs. B. The majority of patients were married (n=118; 64.8%), and of 
White-British ethnicity (n=173; 95.1%). No significant differences were observed between 
the intervention and control groups with respect to age distribution, the gender distribution, in 
the baseline scores for MYCAW, EQ5D and PEI, or in any other study parameters. 
Demographic characteristics of participants are summarised in Table 3. ∀
∀
MYCAW: Comparison of Groups from Baseline to Week 2, Week 4 and Week 6 ∀
The mean MYCAW Concern 1 score for both groups improved over 6 weeks (Table 4). The 
overall mean change in score from baseline to Week 2 was 0.368 (median = 0; SD = 1.39). 
The overall mean change in score from baseline to Week 4 was 0.430 (median = 0; SD = 
1.66). The overall mean change in score from baseline to Week 6 was 0.462 (median = 0; SD 
= 1.59). There were no significant differences (no detectable effect) between the control and 
intervention groups in the change in mean MYCAW 1 scores at 2, 4, or 6 weeks follow up.   
 
There was, however, a significant difference in the rankings for the change in MYCAW 
Concern 1 score [baseline to Week 2] of patients in Groups A (Intervention: mean rank of 
patients: 61.21) and B (Control: mean rank of patients: 75.37) (Mann Whitney Z = -2.192; p 
= 0.028; n = 136). Overall patients in Group B (Control) showed greater improvement or less 
deterioration in the MYCAW score than patients in Group A (Intervention). The mean 
change in MYCAW Concern 1 score [baseline to Week 2] in Group A (Intervention) was 
0.15 (SD = 1.32; median = 0) [a small improvement] vs. Group B (Control) was 0.57 (SD = 
1.44; median = 0). When the scores for changes in MYCAW Concern 1 score for the patients 
were re-coded [baseline to week 2] into groups for deterioration/ no change / improvement, 
there was a statistically significant association between the change in MYCAW Concern 1 
score and study arm (χ
2
trend = 5.51; df = 1; p = 0.019). A higher proportion of patients in 
Group B (Control: 34/70 (48.6%) had an improvement in the MYCAW Concern 1 score 
[baseline to Week 2] compared with patients in Group A (Intervention: 19/66 (28.8%). A 
!∀!∀#!∃
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higher proportion of patients in Group A (Intervention:16/66; 24.2%) showed a deterioration 
in the MYCAW Concern 1 score [baseline to Week 2], compared with patients in Group B 
(Control: 10/70 (14.3%). A higher proportion of patients in Group B (Control:34/70; 48.6%) 
showed an improvement in the MYCAW Concern 1 score [baseline to Week 2], compared 
with patients in Group A (Intervention: 19/66 (28.8%). There was a no significant difference 
in the rankings for the change in MYCAW Concern 1 score from Baseline to Week 4, or 
from Baseline to Week 6.  
∀
MYCAW concerns at baseline∀
Of the 182 patients completing baseline questionnaires, 173 (173/182, 95.1%) respondents 
nominated and scored a primary concern and 125 (125/182, 68.7%) nominated and scored a 
secondary concern. For both∀MYCAW primary and secondary concerns physical symptoms, 
condition and disability predominated, but other concerns such as apprehension for 
themselves or others, concerns about disease progression and dying, feelings of loss of 
function or purpose, and on help needed are also prominent. Similarities were marked, in that 
for all groups, symptoms, condition and disability feature most strongly. For cancer survivors, 
and those receiving end of life cancer care, all concerns were named: apprehension for 
themselves or others; concerns related to the progression of disease; psychological concerns; 
concerns related to loss or existential issues; concerns about needing help; the effect on their 
social life; work or financial issues; and treatment effects.  
∀
EQ5D variables ∀
Comparison of Groups from Baseline to week 2, week 4 and week 6 !
There were no meaningful or significant associations between any of the EQ5D domains for 
Groups A (Intervention) and B (Control) at baseline, Weeks 2, 4 or 6. Table 5 shows the 
frequency of responses for the EQ5D domains at baseline and Weeks 2, 4 and 6. It is also 
worth noting that, in this analysis, the mean EQ5D scores are not changing in any significant 
or meaningful way.∀
∀
PEI scores∀
Comparison of Groups from Baseline to week 2, week 4 and week 6∀
Table 6 shows the distribution of responses for the PEI questions at baseline and Weeks 2, 4 
and 6 respectively in Groups A (Intervention) and B (Control), and in the total sample. There 
were no meaningful or significant associations between the PEI responses to the questions for 
the two groups A (Intervention) and B (Control) or in the total sample (A plus B) at any of 
the time points. 
 
Discussion 
The unexpected negative finding that a higher proportion of patients in the control group 
(34/70; 48.6%) showed an improvement in their MYCAW score from baseline to Week 2 
compared with patients in the intervention group (19/66; 28.8%) (p=0.019) raises questions 
about the application of SPARC and possibly other holistic needs assessment questionnaires 
in the context of a specialist palliative care service.  
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No positive effect of the intervention on either the primary or secondary outcome measures 
was observed at two, four or six weeks, suggesting that the intervention did not have a 
detectable beneficial effect at any point and the difference between arms was obliterated 
when the control arm received SPARC.  
 
Data that indicate that most patients felt that no particular action or benefit followed from the 
completion of SPARC will be reported elsewhere. There were no meaningful or significant 
differences between the control and intervention groups in the scores for health-related 
quality of life as recorded in the general measure EQ5D. This measure did not significantly 
change over the six weeks, as would be expected of patients attending palliative care service. 
However, in contrast, there appears to be improvement in the most important concern as 
recorded in MYCAW, this suggests that ‘usual’ palliative care is having a beneficial effect in 
this respect.  
 
Results in context of other studies   
Several other studies have examined the clinical utility of some holistic needs assessment 
tools. These tools include:  1) Palliative Care Assessment Tool (PACA),
35, 36
 2) The Initial 
Health Assessment (IHA),
37
 and 3) Needs at the End of Life Screening Tool (NEST).
38 
Although the studies have measured changes in clinical outcomes following needs 
assessment, no controlled study has demonstrated an improvement in clinical or patient 
reported outcomes as result of the intervention. Although many of these studies demonstrated 
an improvement in documentation of needs, uptake of findings and action following the 
assessment of needs have been described as poor, with no significant overall improvements in 
care outcomes. The reasons for these results are unclear but could be due to the following; 
inadequate power to detect a change; the tools not being comprehensive enough for holistic 
needs assessments; outcomes chosen may have been inappropriate; health care professionals’ 
attitudes, knowledge or skills
39
; as well as timing of and the availability/non availability of 
services.
38
 It is also possible that standardised needs assessments will never supplement the 
quality of care unless properly integrated with the clinical methods and routine care planning 
procedures of the clinical team. Scandrett et al, 2010
38
 proposed that new methods to achieve 
practice change should be considered and evaluated when assessing such interventions.
7
 
 
Limitations of the study 
Our poor recruitment of patients within the hospital support service meant our study sample 
had fewer patients with conditions other than cancer and a smaller proportion of patients 
acutely ill than the whole population of patients referred to the palliative care service.  
 
The context of a specialist palliative care service is possibly the most difficult environment to 
test an assessment intervention, in that the existing holistic needs assessments may be 
sufficient to detect all issues that require attention. The SPARC pilot trial focussed primarily 
on outcomes, not on the processes involved in implementing the intervention. The MRC 
framework requires an evaluation of the pilot study and a process evaluation is underway and 
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will be reported elsewhere, in order to elucidate the precise mechanism by which this result 
came about.  
 
Conclusions 
This trial result identifies a potential negative effect of SPARC in specialist palliative care 
services, raising questions that standardised holistic needs assessment questionnaires may be 
counter-productive if not integrated with a clinical assessment that informs the care plan.  It 
may raise expectations that are not subsequently met. 
 
We can, however, conclude that a larger trial with more power to detect an effect is highly 
unlikely to be positive. A larger trial in specialist outpatient or home care services, employing 
the same design and outcome measures is unlikely to demonstrate any benefit.  
 
It is nevertheless possible that SPARC has utility for the original purpose for which it was 
designed, as a screening tool, in primary care or general medical care for selection of patients 
who may benefit from a referral to specialist palliative care. It is also possible that were 
SPARC to be included, in the routine clinical assessment that informs a care plan within a 
specialist service then immediate benefit might follow within an effective supportive or 
palliative care service.  
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Table 1 Follow up procedure  
 
 
baseline 
Randomisation 
Group A 
intervention group 
 
MYCAW; EQ-5D; PEI 
SPARC 
Group B 
waiting–list control 
(waiting list) 
MYCAW; EQ-5D; PEI 
 
2 weeks 
 
MYCAW; EQ-5D; PEI 
 
Invitation for patient interview 
MYCAW; EQ-5D; PEI; 
SPARC 
 
4 weeks 
 
MYCAW; EQ-5D; PEI 
plus supplementary question on 
experience of completing the SPARC 
MYCAW; EQ-5D; PEI 
 
Invitation for patient interview 
6 weeks MYCAW; EQ-5D; PEI 
 
MYCAW; EQ-5D; PEI 
plus supplementary question on experience 
of completing the SPARC 
8 weeks Case Note Reviews 
Semi-Structured Interviews with Patients  
Semi-Structured Interviews with Health Care Professionals  
 
SPARC: Sheffield Profile for Assessment and Referral for Care  
MYCAW: Measure Yourself Concerns and Wellbeing  
EQ-5D: Standardised outcome measure of Health Related Quality of Life  
PEI: Patient Enablement Instrument 
  
Figure 1 Summary of recruitment for the SPARC trial 
 
 
Figure 1: Summary of recruitment for the SPARC trial 
There was no significant difference in the number of deaths between the intervention and 
control groups. In Group A (Intervention), nine people (10.3%) died within the 8-week study 
period and in Group B (Control), 14 people (14.7%) died within the 8-week study 
period!!!! ! !!!!∀!!∀ ! !!!! ! !!!!∀#!.  
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At Follow up 
2 week: n= 73 
4 week: n= 62 
6 week: n= 57 
Died n=9 
 
 
850 invitations 
225 patients consented  
randomly allocated to receiving 
SPARC at baseline or SPARC at 2 
weeks  
Control 
N=95 (baseline) 
 
Intervention 
N=87 (baseline) 
 
At Follow up 
2 week: n=79 
4 week: n=64 
6 week: n=63 
Died n=14 
 
43 patients lost to follow up after 
consenting to study and prior to completion 
of baseline questionnaires, either due to 
illness/poor prognosis, being discharged 
from service/setting or declined to take any 
further part in the trial. 
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Table 2 Research questionnaires: Rationale for choice of outcome measures 
MYMOP  
(Measure Yourself Medical Outcomes Profile) 
MYCAW  
(Measure Yourself Concerns and Wellbeing) 
Slightly modified version of MYCAW used  
EQ-5D 
(Health-related quality of life outcome measure) 
PEI 
(Patient Enablement Instrument) 
Slightly modified version of PEI used  
! A precursor of MYCAW. 
! Demonstrated sensitivity to change.  
! Used in a range of contexts.  
! Patient self-complete, outcome questionnaire, problem-
specific (includes general wellbeing). 
! Applicable to all symptomatic patients. 
! Brief and simple questionnaire to administer.  
! MYCAW used in preference to MYMOP because 
concerns raised could be of any kind, and not restricted to 
symptoms or activity (may be of significance when 
comparing the information from the three groups: cancer 
survivors, people with long term conditions and people 
needing end-of-life care).  
! For the purposes of this study it was important to use an 
outcome measure which covered the diversity in the 
patient group. 
! A slightly modified version of MYCAW was used (the 
sentence “Please write down one or two concerns or 
problems which you would most like us to help you with” 
was replaced with “Please write down one or two 
concerns or problems that bother you most”). 
 
References 
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! Developed from a validated tool MYMOP, simple to use 
and sensitive enough to show any changes with time.  
! Patients nominate concerns, which may or may not be 
medical (MYCAW) or symptoms (MYMOP) of 
importance to them (two concerns/symptoms can be 
identified). 
! They then score these on a scale of 0 (not bothering me at 
all) - 6 (bothers me greatly).  
! Patients are also asked to rate their general feeling of 
wellbeing on a scale of 0 (as good as it could be) - 6 (as 
bad as it could be).  
! The follow-up form asks patients to re-score the 
concerns/symptoms, and rate their general feeling of 
wellbeing they previously nominated, thus capturing any 
changes over time that are important to the patient.  
! However, HRQoL may not be sensitive enough to 
changes in the short term, possibly because people adjust 
their expectations.  
! Work by Guyatt et al (1998) indicates that in seven-point 
scales of this kind, a shift of one point corresponds to a 
moderately important change for a patient.  
! Is an additional element of needs assessment, stated 
concerns, are truly patient generated, reflecting an 
accurate expression of need at that time. 
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! Outcome measure of health-related quality of life. 
! Patient self-complete. 
! Five questions (3 varying response categories): on 
mobility, self-care, usual activities (e.g. work, study, 
housework, family, or leisure activities), pain/discomfort 
and anxiety/depression.  
! A further question (EQ-5D thermometer scale) asks 
people to mark their current health status on a scale of 0 
(worst imaginable health state)-100 (best imaginable 
health state). 
! Used extensively in studies where quality of life is 
compared between patient groups.  
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!
! Outcome measure of a patient’s ability to cope with life 
and their illness and the confidence and ability to help 
themselves (as a result of visiting a doctor or health 
professional). 
! Patient self-complete. 
! One main question “thinking about the last time you 
saw a doctor or nurse from palliative care, do you feel 
you are:...(6 sub-questions with 4 varying response 
categories).  
! Studies in general practice to assess quality of 
consultations using PEI, have shown it to be a crucial 
outcome measure, with enablement correlating best 
with the length of consultation and how well the patient 
knew the doctor. 
! PEI scores consultations in cancer clinics, 
independently of quality of life and scores higher when 
sufficient time is allocated or when staff have 
communication skills training (our own unpublished 
work).  
! PEI may detect an effect of SPARC (if any) on the 
quality of subsequent consultations with the clinical 
team.  
! A measure of consultation quality was included in order 
to detect an effect on communication between patients 
and professionals. However, we overestimated the 
intensity of contact between patients and professionals 
and palliative care services in the duration of this trial. 
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Table 3: Information relating to baseline demographic characteristics of participants in 
Group A (Intervention), Group B (Control) and in Total Sample (A plus B).  
 
Characteristic  Intervention Group 
A 
n, (%) 
Control Group B 
n, (%) 
All patients, n Notes A vs B 
p 
Age (mean age 
in years) on 
registration  
63.90 years (median = 
65.00 years; SD = 
11.68; minimum age = 
28 years; maximum 
age = 87 years).  
64.99 years (median = 
67.00 years; SD = 13.34; 
minimum age = 27 
years; maximum age = 
90 years). 
64.47 years (median = 
66.00 years; SD = 12.57; 
minimum age = 27 
years; maximum age = 
90 years). 
No significant difference (Mann-Whitney Z = -
0.865; p = 0.387).  
 
Gender  No significant difference !!! ! !!!∀#!!∀ !
!!! ! ! !!!!∀∀!. Male  36 (41.4%) 48 (50.5%) 84 (46.2%) 
Female  51 (58.6%) 47 (49.5%) 98 (53.8%) 
Total  87 (47.8%) 95 (52.2%) 182   
Partnership / 
Marital status 
 No significant difference !!! ! !!!∀#!!∀ !
!!! !! ! !!!∀!!. The majority of patients were 
married (n=118; 64.8%). Married 56 (64.4) 62 (65.3) 118 (64.8) 
Single 10 (11.5) 7 (7.5) 17 (9.5) 
Divorced/parte
d/separated 
5 (5.8) 9 (.7) 14 (7.8) 
Widowed 15 (17.4) 15 (16.1) 30 (16.8) 
Total 86 (100) 93 (100) 179 (100) 
Unknown: 3 (……) 
Ethnicity   
White – British 83 (95.4) 90 (94.7) 173 (95.1) The low numbers in many of the groups meant 
that it was not possible to test for differences. 
 
White – other 
background 
2 (2.3) 0 (-) 2 (1.1) 
Black or Black 
British 
Caribbean 
1 (1.1) 0 (-) 1 (0.5) 
Asian or Asian 
British-Indian 
0 (-) 1 (1.1) 1 (0.5) 
Information 
withheld/not 
documented 
1 (1.1) 4 (4.2) 5 (2.7) 
Total 87 (100) 95 (100) 182 (100) 
Living 
arrangements 
 The majority of patients were living at home 
(n=177; 97.3%), three patients were living in a 
care or nursing home (1.6%), and for two 
patients (1.1%) it was not known where they 
were living. 
Home 83 (96.5) 94 (100) 177 (98.3) 
Care 
home/nursing 
home 
3 (3.5) 0 (-) 3 (1.7) 
Total 
 
 
86 (100) 94 (100) 180 (100) 
Patient lives 
alone 
 No significant difference in the proportions of 
patients living alone !!! ! !!!∀!!!∀ !
!!! ! ! !!!!!∀!!  Living alone 15 /73 (20.5%) 20/88 (22.7%) 35 (19.2%) 
Religion  The majority of the patients (n=115; 63.2%) 
gave their religious denomination as Church of 
England.   
 
 
 
Church of 
England 
56 (64.4) 59 (62.1) 115 (63.2) 
Roman 
Catholic 
6 (6.9) 5 (5.3) 11 (6.0) 
Christian 5 (5.7) 7 (7.4) 12 (6.6) 
Jewish 2 (2.3) 2 (2.1) 4 (2.2) 
Methodist 3 (3.4) 4 (4.2) 7 (3.8) 
Protestant 1 (1.1) 1 (1.1) 2 (1.1) 
Humanist 1 (1.1) 0 (-) 1 (0.5) 
Anglican 1 (1.1) 0 (-) 1 (0.5) 
Agnostic 0 (-) 2 (2.1) 2 (1.1) 
Quaker 1 (1.1) 2 (2.1) 3 (1.6) 
Church of 
Scotland 
1 (1.1) 0 (-) 1 (0.5) 
None 10 (11.5) 13 (13.7) 23 (12.6) 
Total 87 (100) 95 (100) 182 (100) 
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Table 4 Shows the distribution of scores for MYCAW concern 1 at baseline and at 2, 4 and 
6-week follow-up in Group A (Intervention), Group B (Control) and for the Total Sample 
(Group A plus Group B). 
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Table 5 Frequency of EQ5D responses in Groups A (Intervention) and B (Control) and Total 
Sample (A plus B) at Baseline, Weeks 2, 4 and 6. 
 
 
 
Domain Response n (%) Baseline Week 2 Week 4 Week 6 
Group  A B ∃%&∋( A B ∃%&∋( A B ∃%&∋( A B ∃%&∋( 
Mobility I have no problems in walking 
about 
13 (15.7) 9 (9.5) 22 (12.4) 11 (15.1) 10 (13.0) 21 (14.0) 10 (16.9) 8 (12.5) 18 (14.6) 8 (14.3) 5 (7.9) 13 (10.9) 
I have some problems in 
walking about 
66 (79.5) 85 (89.5) 151 
(84.8) 
60 (82.2) 64 (83.1) 124 
(82.7) 
48 (81.4) 53 (82.8) 101 
(82.1) 
45 (80.4) 56 (88.9) 101 
(55.5) 
I am confined to bed 4 (4.8) 1 (1.1) 5 (2.8) 2 (2.7) 3 (3.9) 5 (3.3) 1 (1.7) 3 (4.7) 4 (3.3) 3 (5.4) 2 (3.2) 5 (2.7) 
Total 83 (100) 95 (100) 178 (100) 73 (100) 77 (100) 150 (100) 59 (100) 64 (100) 123 (100) 56 (100) 63 (100) 119 (100) 
Self-care I have no problems with self 
care 
43 (53.1) 43 (45.3) 86 (48.9) 37 (51.4) 36 (46.8) 73 (49.0) 34 (57.6) 28 (44.4) 62 (50.8) 31 (55.4) 27 (42.9) 58 (48.7) 
I have some problems 
washing or dressing myself 
33 (40.7) 48 (50.5) 81 (46.0) 31 (43.1) 36 (46.8) 67 (45.0) 22 (37.3) 33 (52.4) 55 (45.1) 20 (35.7) 33 (52.4) 53 (44.5) 
I am unable to wash or dress 
myself 
5 (6.2) 4 (4.2) 9 (5.1) 4 95.6) 5 (6.5) 9 (6.0) 3 (5.1) 2 (3.2) 5 (4.1) 5 (8.9) 3 (4.8) 8 (6.7) 
Total 81 (100) 95 (100) 176 (100) 72 (100) 77 (100) 149 (100) 59 (100) 63 (100) 122 (100) 56 (100) 63 (100) 119 (100) 
Usual  
Activities 
I have no problems with 
performing my usual activities 
7 (8.4) 6 (6.5) 13 (7.4) 7 (9.7) 8 (10.3) 15 (10.0) 3 (5.1) 8 (12.5) 11 (8.9) 4 (7.4) 7 (11.1) 11 (9.4) 
I have some problems with 
performing my usual activities 
54 (65.1) 59 (63.4) 113 
(64.2) 
46 (63.9) 49 (62.8) 95 (63.3) 40 (67.8) 38 (59.4) 78 (63.4) 31 (57.4) 40 (63.5) 71 (60.7) 
I am unable to perform my 
usual activities 
22 (26.5) 28 (30.1) 20 (28.4) 19 (26.4) 21 (26.9) 40 (26.7) 16 (27.1) 18 (28.1) 34 (27.6) 19 (35.2) 16 (25.4) 35 (29.9) 
Total 83 (100) 93 (100) 176 (100) 72 (100) 78 (100) 150 (100) 59 (100) 64 (100) 123 (100) 54 (100) 63 (100) 117 (100) 
Pain  
/discomfort 
I have no pain or discomfort 11 (13.3) 9 (9.8) 20 (11.4) 9 (12.5) 10 (13.2) 19 (12.8) 6 (10.3) 3 (4.8) 9 (7.5) 8 (14.8) 4 (6.6) 12 (10.4) 
I have moderate pain or 
discomfort  
59 (71.1) 72 (78.3) 131 
(74.9) 
55 (76.4) 55 (72.4) 110 
(74.3) 
44 (75.9) 54 (87.1) 98 (81.7) 34 (63.0) 53 (86.9) 87 (75.7) 
I have extreme pain or 
discomfort 
13 (15.7) 11 (12.0) 24 (13.7) 8 (11.1) 11 (14.5) 19 (12.8) 8 (13.8) 5 (8.1) 13 (10.8) 12 (22.2) 4 (6.6) 16 (13.9) 
Total 83 (100) 92 (100) 175 (100) 72 (100) 76 (100) 148 (100) 58 (100) 62 (100) 120 (100) 54 (100) 61 (100) 35 (29.9) 
Anxiety / 
depression 
I am not anxious or depressed 34 (42.0) 29 (31.9) 63 (36.6) 31 (43.1) 23 (29.9) 54 (36.2) 23 (40.4) 18 (29.0) 41 (34.5) 19 (34.5) 23 (37.7) 42 (36.2) 
I am moderately anxious or 
depressed 
42 (51.9) 55 (60.4) 97(56.4) 37 (51.4) 52 (67.5) 89 (59.7) 31 (54.4) 41 (66.1) 72 (60.5) 29 (52.7) 34 (55.7) 63 (54.3) 
I am extremely anxious or 
depressed 
5 (6.2) 7 (7.7) 12 (7.0) 4 (5.6) 2 (2.6) 6 (4.0) 3 (5.3) 3 (4.8) 6 (5.0) 7 (12.7) 4 (6.6) 11 (9.5) 
Total 81 (100) 91 (100) 172 (100) 72 (100) 77 (100) 149 (100) 57 (100) 62 (100) 119 (100) 55 (100) 61 (100) 116 (100) 
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Table 6 There were no meaningful or significant associations between the PEI responses to the questions and the two groups A (Intervention) and B (Control) and in 
the total sample at baseline, week 2, week 4, or week 6 respectively. 
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Appendix 1 
SPARC 
 
 
 
 
 
 
 
We would like to know a bit more about you and your 
concerns. Please fill in the questionnaire overleaf (with 
help from a relative or carer if needed) and return it with 
the study questionnaire booklet. There are no “right” or 
“wrong” answers. If you are unsure of a question, 
please leave it blank.  
 
 
 
 
THANK YOU. 
 
SPARC* 
We would like to know a bit more about you and your concerns. Please fill in this questionnaire (with help from a 
relative or carer if needed) and return it with the study questionnaire booklet. There are no “right” or “wrong” 
answers. If you are unsure of a question, please leave it blank. THANK YOU. 
 
COMMUNICATION AND INFORMATION ISSUES 
1. Have you been able to talk to any of the following people about your condition? 
a. Your doctor 
 
b. Community nurse 
c. Hospital nurse 
d. Religious advisor 
e. Social worker 
f. Family 
 
g. Other people (please state) 
Yes No 
 
Please circle one answer per line 
PHYSICAL SYMPTOMS 
 
In the past month have you been distressed or bothered by 
 
Not at 
all 
 
A little 
bit 
 
Quite a 
bit 
 
Very 
much 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
7. 
 
8. 
 
9. 
 
10. 
 
11. 
 
12. 
 
13. 
 
14. 
 
15. 
 
16. 
 
17. 
 
18. 
 
19. 
 
20. 
 
21. 
 
22. 
Pain? 
 
Loss of memory? 
Headache? 
Dry mouth? 
 
Sore mouth? 
Shortness of breath? 
Cough? 
Feeling sick (nausea)? 
Being sick (vomiting)? 
Bowel problems (eg constipation, diarrhoea or incontinence)? 
 
Bladder problems (urinary incontinence)? 
Feeling weak? 
Feeling tired? 
 
Problems sleeping at night? 
Feeling sleepy during the day? 
Loss of appetite? 
Changes in your weight? 
Problems with swallowing? 
Being concerned about changes in your appearance? 
 
Feeling restless and agitated? 
 
Feeling that your symptoms are not controlled? 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
0 1 2 3 
 
PSYCHOLOGICAL ISSUES 
In the past month have you been distressed or bothered by 
23. 
 
24. 
 
25. 
 
26. 
 
27. 
 
28. 
 
29. 
 
30. 
 
31. 
Feeling anxious? 
 
Feeling as if you are in a low mood? 
Feeling confused? 
Feeling unable to concentrate? 
 
Feeling lonely? 
 
Feeling that everything is an effort? 
Feeling that life is not worth living? 
Thoughts about ending it all? 
The effect of your condition on your sexual life? 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
*Sheffield Profile for Assessment and Referral to Care 
SPARC-45(clinical) v1          July 2005 © The University of Sheffield - Academic Unit of Supportive Care                                                                          
  
37. Feeling that people do not understand what you want? 0 1 2 3 
38. Worrying about the effect that your illness is having on your 
family or other people? 
 
0 
 
1 
 
2 
 
3 
39. Lack of support from your family or other people? 0 1 2 3 
40. Needing more help than your family or other people could giv ? 0 1 2 3 
 
Please circle one answer per line 
 
 
RELIGIOUS AND SPIRITUAL ISSUES 
In the past month have you been distressed or bothered by 
 
Not at 
all 
 
A little 
bit 
 
Quite a 
bit 
 
Very 
much 
32. 
 
33. 
Worrying thoughts about death or dying? 
 
Religious or spiritual needs not being met? 
0 1 2 3 
 
0 1 2 3 
 
INDEPENDENCE AND ACTIVITY 
In the past month have you been distressed or bothered by 
34. 
 
35. 
 
 
36. 
Losing your independence? 
 
Changes in your ability to carry out your usual daily activities such 
as washing, bathing, or going to the toilet? 
 
Changes in your ability to carry out your usual household tasks 
such as cooking for yourself or cleaning the house? 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
FAMILY AND SOCIAL ISSUES 
In the past month have you been distressed or bothered by 
 
 
 
 
 
 
e 
 
TREATMENT ISSUES 
In the past month have you been distressed or bothered by 
41. Side effects from your treatment? 0 1 2 3 
42. Worrying about long term effects of your treatment? 0 1 2 3 
 
PERSONAL ISSUES 
 
 
Yes No 
43. 
 
44. 
45. 
Do you need any help with your personal affairs? 
 
Would you like to talk to another professional about your condition or treatment? 
Would you like any more information about the following? 
a. Your condition 
b. Your care 
c. Your treatment 
 
d. Other types of support 
e. Financial issues 
f. Other (please state) 
 
Are there any other concerns you would like us to know about? 
 
 
 
 
 
 
 
 
 
This form was completed by: 
Name [Please print] 
 
Patient / Carer / Professional* 
 
*circle as appropriate 
 
 
Date 
FOR OFFICE USE ONLY 
 
*Sheffield Profile for Assessment and Referral to Care 
SPARC-45(clinical) v1 July 2005 © The University of Sheffield - Academic Unit of Supportive Care 
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